RT info:eu-repo/semantics/article
T1 Population-based registry analysis of antidiabetics dispensations: trend use in Spain between 2015 and 2018 with reference to driving
A1 Gutiérrez Abejón, Eduardo
A1 Criado Espegel, Paloma
A1 Herrera Gómez, Francisco Magno
A1 Álvarez González, Francisco Javier
K1 Diabetes
K1 Diabetes mellitus
K1 Insulin
K1 Medicamentos - Efectos fisiológicos
K1 Diabetes - Tratamiento
K1 Automoviles - Conducción
K1 Drugged driving - OECD countries
K1 3209 Farmacología
AB Insulins and some oral antidiabetics are considered to be driving-impairing medicines (DIM) and they belong to the Driving under the Influence of Drugs, alcohol, and medicines (DRUID) category I (minor influence on fitness to drive). The trend of antidiabetics use in Castilla y León from 2015 to 2018 is presented through a population-based registry study. Treatment duration with these medicines and the concomitant use of other DIMs were observed. An adjustment method was used with information from the drivers’ license census. For all calculations, age and gender were taken into account. 3.98% of the general population used at least one antidiabetic, as well as 2.92% of drivers. The consumption of antidiabetics in men was higher than in women (4.35% vs. 3.61%, p = 0.001), and the use increases with age, especially from 35–39 years to 75–79 years in men and 85–89 years in women. Antidiabetics were consumed chronically, specifically 100% in the case of insulins and 95% in the case of oral antidiabetics. In addition to antidiabetics, 2.5 ± 1.86 DIMs were consumed, mainly anxiolytics (25.53%), opioids (23.03%), other analgesics and antipiretics (19.13%), and antidepressants (17.73%). Collaboration between pharmacists and physicians is a priority to clearly transmitting risks to patients. It is necessary that the health authorities include information on DIMs, such as the DRUID classification, in the prescription and dispensing software.
PB MDPI
SN 1424-8247
YR 2020
FD 2020
LK https://uvadoc.uva.es/handle/10324/58918
UL https://uvadoc.uva.es/handle/10324/58918
LA eng
NO Pharmaceuticals, 2020, Vol. 13, Nº. 8, 165
NO Producción Científica
DS UVaDOC
RD 17-may-2024